NO861139L - Stabilt gamma-interferonpreparat. - Google Patents

Stabilt gamma-interferonpreparat.

Info

Publication number: NO861139L
Authority: NO; Norway
Prior art keywords: solution; interferon; preparation; preparation according; gif
Prior art date: 1985-03-25

Application number

NO861139A

Other languages

English (en)

Norwegian (no)

Inventor

Zachary Yim

Imtiaz Ahmad Chaudry

Original Assignee

Schering Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1985-03-25

Filing date

1986-03-21

Publication date

1986-09-26

1986-03-21 Application filed by Schering Corp filed Critical Schering Corp

1986-09-26 Publication of NO861139L publication Critical patent/NO861139L/no

Links

238000002360 preparation method Methods 0.000 title claims description 36
229940044627 gamma-interferon Drugs 0.000 title claims description 6
108010074328 Interferon-gamma Proteins 0.000 title description 2
102000008070 Interferon-gamma Human genes 0.000 title description 2
239000000243 solution Substances 0.000 claims description 47
229940079322 interferon Drugs 0.000 claims description 18
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 12
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 10
239000000872 buffer Substances 0.000 claims description 10
230000007935 neutral effect Effects 0.000 claims description 10
239000003963 antioxidant agent Substances 0.000 claims description 9
235000006708 antioxidants Nutrition 0.000 claims description 9
239000003795 chemical substances by application Substances 0.000 claims description 9
238000003860 storage Methods 0.000 claims description 9
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
230000003078 antioxidant effect Effects 0.000 claims description 8
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 7
235000018417 cysteine Nutrition 0.000 claims description 7
102000008100 Human Serum Albumin Human genes 0.000 claims description 6
108091006905 Human Serum Albumin Proteins 0.000 claims description 6
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 6
239000000203 mixture Substances 0.000 claims description 6
150000003839 salts Chemical class 0.000 claims description 6
235000001014 amino acid Nutrition 0.000 claims description 5
150000001413 amino acids Chemical class 0.000 claims description 5
229960005070 ascorbic acid Drugs 0.000 claims description 5
235000010323 ascorbic acid Nutrition 0.000 claims description 5
239000011668 ascorbic acid Substances 0.000 claims description 5
239000004471 Glycine Substances 0.000 claims description 4
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 4
229940061607 dibasic sodium phosphate Drugs 0.000 claims description 4
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 4
238000007710 freezing Methods 0.000 claims description 4
230000008014 freezing Effects 0.000 claims description 4
238000000034 method Methods 0.000 claims description 4
239000002904 solvent Substances 0.000 claims description 4
230000008961 swelling Effects 0.000 claims description 4
ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims description 3
102000006992 Interferon-alpha Human genes 0.000 claims description 3
108010047761 Interferon-alpha Proteins 0.000 claims description 3
102000003996 Interferon-beta Human genes 0.000 claims description 3
108090000467 Interferon-beta Proteins 0.000 claims description 3
238000002347 injection Methods 0.000 claims description 3
239000007924 injection Substances 0.000 claims description 3
239000007853 buffer solution Substances 0.000 claims description 2
239000003638 chemical reducing agent Substances 0.000 claims description 2
150000002016 disaccharides Chemical class 0.000 claims description 2
150000002772 monosaccharides Chemical class 0.000 claims description 2
150000005846 sugar alcohols Chemical class 0.000 claims description 2
125000003396 thiol group Chemical group [H]S* 0.000 claims description 2
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 1
239000003349 gelling agent Substances 0.000 claims 1
239000002023 wood Substances 0.000 claims 1
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
230000002378 acidificating effect Effects 0.000 description 8
239000008364 bulk solution Substances 0.000 description 8
108010050904 Interferons Proteins 0.000 description 7
102000014150 Interferons Human genes 0.000 description 7
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
230000008901 benefit Effects 0.000 description 5
239000008176 lyophilized powder Substances 0.000 description 5
239000002244 precipitate Substances 0.000 description 5
229940024606 amino acid Drugs 0.000 description 4
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
230000001028 anti-proliverative effect Effects 0.000 description 3
229960002433 cysteine Drugs 0.000 description 3
239000002552 dosage form Substances 0.000 description 3
229940047124 interferons Drugs 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
101800000263 Acidic protein Proteins 0.000 description 2
239000012670 alkaline solution Substances 0.000 description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
230000000120 cytopathologic effect Effects 0.000 description 2
238000004108 freeze drying Methods 0.000 description 2
239000008103 glucose Substances 0.000 description 2
-1 glucose) Chemical class 0.000 description 2
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
230000004957 immunoregulator effect Effects 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
238000010255 intramuscular injection Methods 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
239000000843 powder Substances 0.000 description 2
239000000047 product Substances 0.000 description 2
230000002035 prolonged effect Effects 0.000 description 2
238000005057 refrigeration Methods 0.000 description 2
238000010561 standard procedure Methods 0.000 description 2
KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
238000010257 thawing Methods 0.000 description 2
QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
206010011732 Cyst Diseases 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
108010024636 Glutathione Proteins 0.000 description 1
101000599940 Homo sapiens Interferon gamma Proteins 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
208000007536 Thrombosis Diseases 0.000 description 1
241000700605 Viruses Species 0.000 description 1
239000002253 acid Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
239000003708 ampul Substances 0.000 description 1
230000000840 anti-viral effect Effects 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
230000008827 biological function Effects 0.000 description 1
KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
239000004327 boric acid Substances 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
239000005018 casein Substances 0.000 description 1
BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
235000021240 caseins Nutrition 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
208000031513 cyst Diseases 0.000 description 1
229960001305 cysteine hydrochloride Drugs 0.000 description 1
150000001945 cysteines Chemical class 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
239000012634 fragment Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
238000001879 gelation Methods 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
229960003180 glutathione Drugs 0.000 description 1
125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
229940102223 injectable solution Drugs 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
239000000644 isotonic solution Substances 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
239000000463 material Substances 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
150000004682 monohydrates Chemical class 0.000 description 1
239000007922 nasal spray Substances 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
239000013049 sediment Substances 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
235000011008 sodium phosphates Nutrition 0.000 description 1
230000003381 solubilizing effect Effects 0.000 description 1
238000012430 stability testing Methods 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000001384 succinic acid Substances 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
UVZICZIVKIMRNE-UHFFFAOYSA-N thiodiacetic acid Chemical compound OC(=O)CSCC(O)=O UVZICZIVKIMRNE-UHFFFAOYSA-N 0.000 description 1
230000001256 tonic effect Effects 0.000 description 1
239000006208 topical dosage form Substances 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical class [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/217—IFN-gamma
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Dermatology (AREA)
General Chemical & Material Sciences (AREA)
Oil, Petroleum & Natural Gas (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

NO861139A 1985-03-25 1986-03-21 Stabilt gamma-interferonpreparat. NO861139L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US71585185A	1985-03-25	1985-03-25
US74093285A	1985-06-03	1985-06-03

Publications (1)

Publication Number	Publication Date
NO861139L true NO861139L (no)	1986-09-26

Family

ID=27109430

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO861139A NO861139L (no)	1985-03-25	1986-03-21	Stabilt gamma-interferonpreparat.

Country Status (17)

Country	Link
EP (1)	EP0196203A3 (fr)
KR (1)	KR900004799B1 (fr)
CN (1)	CN86101878A (fr)
AU (1)	AU592552B2 (fr)
DK (1)	DK131986A (fr)
ES (1)	ES8705761A1 (fr)
FI (1)	FI861193A (fr)
GR (1)	GR860758B (fr)
HU (1)	HU200278B (fr)
IL (1)	IL78231A (fr)
MA (1)	MA20647A1 (fr)
MY (1)	MY101973A (fr)
NO (1)	NO861139L (fr)
NZ (1)	NZ215563A (fr)
OA (1)	OA08269A (fr)
PT (1)	PT82249B (fr)
TN (1)	TNSN86042A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5037644A (en) *	1986-10-27	1991-08-06	Cetus Corporation	Pharmaceutical compositions of recombinant interleukin-2 and formulation processes
US5183746A (en) *	1986-10-27	1993-02-02	Schering Aktiengesellschaft	Formulation processes for pharmaceutical compositions of recombinant β-
EP0284249A1 (fr) *	1987-03-13	1988-09-28	Interferon Sciences, Inc.	Composition lyophilisée de lymphokine
US5151265A (en) *	1987-11-03	1992-09-29	Genentech, Inc.	Gamma interferon formulation
US5004605A (en) *	1987-12-10	1991-04-02	Cetus Corporation	Low pH pharmaceutical compositions of recombinant β-interferon
CA2024046A1 (fr) *	1989-09-28	1991-03-29	Alberto Ferro	Interferons stabilises
FR2690340B1 (fr) *	1992-04-24	1995-02-24	Scr Newmed	Nouveau procédé de stabilisation des préparations pharmaceutiques liquides et les compositions pharmaceutiques ainsi stabilisées en résultant.
TW249202B (fr) *	1993-08-13	1995-06-11	Ciba Gerigy Corp
US20030147850A1 (en) *	2001-09-27	2003-08-07	Pomytkin Igor Anatolievich	Composition and methods for potentiating therapeutic effects of interferons
CU23432B6 (es) *	2005-11-02	2009-10-16	Ct Ingenieria Genetica Biotech	Formulaciones estabilizadas que contienen a los interferones gamma y alfa en proporciones potenciadoras
WO2019059804A1 (fr) *	2017-09-25	2019-03-28	Георгий Георгиевич ЧУМБУРИДЗЕ	Composition thermostable possédant une action antivirale et antibactérienne, et utilisation de celle-ci

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4480032A (en) *	1980-11-13	1984-10-30	Yabrov Alexander A	Natural mixture of Type I and Type II interferons
EP0080879B1 (fr) *	1981-11-28	1986-10-01	Sunstar Kabushiki Kaisha	Composition pharmaceutique contenant de l'interféron stabilisé
ZA83768B (en) *	1982-03-01	1983-10-26	Hoffmann La Roche	Homogeneous human immune interferon and process therefor
DE3484374D1 (de) *	1983-08-04	1991-05-08	Green Cross Corp	Gamma-interferonzusammensetzung.
EP0168008A3 (fr) *	1984-07-10	1986-12-30	Takeda Chemical Industries, Ltd.	Composition stable d'interféron-gamma

1986
- 1986-03-21 GR GR860758A patent/GR860758B/el unknown
- 1986-03-21 TN TNTNSN86042A patent/TNSN86042A1/fr unknown
- 1986-03-21 FI FI861193A patent/FI861193A/fi not_active Application Discontinuation
- 1986-03-21 NO NO861139A patent/NO861139L/no unknown
- 1986-03-21 DK DK131986A patent/DK131986A/da not_active Application Discontinuation
- 1986-03-21 PT PT82249A patent/PT82249B/pt unknown
- 1986-03-21 IL IL78231A patent/IL78231A/xx unknown
- 1986-03-21 ES ES553232A patent/ES8705761A1/es not_active Expired
- 1986-03-21 OA OA58817A patent/OA08269A/fr unknown
- 1986-03-21 AU AU55028/86A patent/AU592552B2/en not_active Ceased
- 1986-03-21 NZ NZ215563A patent/NZ215563A/xx unknown
- 1986-03-21 MA MA20872A patent/MA20647A1/fr unknown
- 1986-03-21 EP EP86302104A patent/EP0196203A3/fr not_active Ceased
- 1986-03-24 HU HU861217A patent/HU200278B/hu not_active IP Right Cessation
- 1986-03-24 CN CN198686101878A patent/CN86101878A/zh active Pending
- 1986-03-24 KR KR1019860002163A patent/KR900004799B1/ko not_active Application Discontinuation
1987
- 1987-08-10 MY MYPI87001253A patent/MY101973A/en unknown

Also Published As

Publication number	Publication date
OA08269A (fr)	1987-10-30
MY101973A (en)	1992-02-29
DK131986A (da)	1986-09-26
EP0196203A3 (fr)	1987-09-30
NZ215563A (en)	1989-06-28
MA20647A1 (fr)	1986-10-01
FI861193A0 (fi)	1986-03-21
CN86101878A (zh)	1986-10-29
AU592552B2 (en)	1990-01-18
PT82249B (en)	1988-01-07
TNSN86042A1 (fr)	1990-01-01
EP0196203A2 (fr)	1986-10-01
DK131986D0 (da)	1986-03-21
PT82249A (en)	1986-04-01
KR860006982A (ko)	1986-10-06
AU5502886A (en)	1986-10-02
KR900004799B1 (ko)	1990-07-06
FI861193A (fi)	1986-09-26
ES553232A0 (es)	1987-05-16
ES8705761A1 (es)	1987-05-16
HU200278B (en)	1990-05-28
IL78231A0 (en)	1986-07-31
IL78231A (en)	1990-07-26
GR860758B (en)	1986-07-21
HUT40577A (en)	1987-01-28

Publication	Publication Date	Title
EP0618807B1 (fr)	2002-11-13	Formulation pharmaceutique stabilisee comportant une somatotrophine et de l'histidine
US4847079A (en)	1989-07-11	Biologically stable interferon compositions comprising thimerosal
JP3898221B2 (ja)	2007-03-28	トレハロースを含む乾燥血液因子組成物
JP4405666B2 (ja)	2010-01-27	安定化テリパラチド溶液剤
JP3031570B2 (ja)	2000-04-10	安定化されたゴナドトロピンを含有する調製品
EP0618806B1 (fr)	1999-03-17	Formulation pharmaceutique stabilisee comprenant une hormone de croissance et de l'asparagine
US5849704A (en)	1998-12-15	Pharmaceutical formulation
US20020077461A1 (en)	2002-06-20	Pharmaceutical formulation
CA2226523A1 (fr)	1997-02-06	Formulation pharmaceutique stabilisee comprenant une hormone de croissance pre-traitee avec des ions zinc et facultativement lysine ou calcium
EP1082133A2 (fr)	2001-03-14	Formulations pharmaceutiques pour igf/igfbp
AU738413B2 (en)	2001-09-20	Human growth hormone-containing aqueous pharmaceutical composition
JP2002511103A (ja)	2002-04-09	アミリン作動薬ペプチド用製剤
NO861139L (no)	1986-09-26	Stabilt gamma-interferonpreparat.
US20050163752A1 (en)	2005-07-28	Human interferon-beta formulations
US8841252B2 (en)	2014-09-23	Pharmaceutical formulation
EP0787497A2 (fr)	1997-08-06	Préparation pharmaceutique contenant l'hormone de croissance humaine
EP1706150B1 (fr)	2012-04-25	Formulation liquide stable d'hormones de croissance
JPH0925241A (ja)	1997-01-28	Ｈｇｆ凍結乾燥製剤
JP2002512973A (ja)	2002-05-08	タンパク質製剤
EP0804223B1 (fr)	1999-09-22	Compositions pharmaceutiques renfermant l'hch
KR880002037B1 (ko)	1988-10-13	인터페론 조성물 및 이의 제조방법
JP2001524360A (ja)	2001-12-04	０．５ｍｌ未満の容量を投与するための凍結乾燥タンパク質組成物を含む１回量注射器
EP0189673A1 (fr)	1986-08-06	Préparation stable de GRF
US5169834A (en)	1992-12-08	Compositions and method for reducing vial breakage during lyophilization
US9387233B2 (en)	2016-07-12	Long-term storage of non-glycosylated recombinant human G-CSF